For a better experience, Read this story in our App
+ 182.34
+ 88.55
-10.00
-1,378.00
-1,327.00
+ 182.34
+ 88.55
+ 88.55
-10.00
-10.00
-1,378.00
Dr Reddy’s Laboratories is likely to post about 15 to 18 per cent growth in its topline and bottomline in the fourth quarter of the financial year 2024-25.
The Hyderabad-based company will announce its fourth quarter and full FY25 numbers today.
Dr Reddy’s Laboratories’ net profit increased 36 per cent to ₹1,307 crore in the fourth quarter ended March 31, 2024, as against ₹959 crore in the year-ago period. This is driven by the increase in US sales that lead to a 12 per cent growth in total revenue at ₹7,083 crore, compared to ₹6,296 crore in the corresponding quarter of the previous year.
The growth during Q4 of FY25 could be positive due to higher traction on the new product launches in the US market which could offset the price erosion.
Published on May 9, 2025
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.